The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the virus causing coronavirus disease 2019 (COVID-19), has been confirmed in cancers through binding specific mRNAs to invade human cells. Therefore, the aim of this study described here was to develop and validate novel SARS-CoV-2 proteins binding human mRNAs (SPBRs) signature to predict overall survival (OS) in hepatocellular carcinoma (HCC). Using multivariate Cox regression analysis, a set of SPBRs was identified to establish a multigene signature in the Cancer Genome Atlas repositories cohort. Furthermore, a nomogram was established based on the signature and clinical risk factors to improve risk stratification for individual patients. External validation was performed in the International Cancer Genome Consortium (ICGC) cohort. A six-SPBR signature was built to classify patients into two risk groups using a risk score with different OS in two cohorts (all p < 0.0001). Multivariate regression analysis demonstrated the signature was an independent predictor of HCC. Moreover, the signature presented an excellent diagnostic power in differentiating HCC and normal tissues. Gene set enrichment analysis demonstrated that high-risk group was closely enriched in cell cycle, DNA replication, microRNAs in cancer, and cytokine–cytokine receptor interaction. The novel signature demonstrated great clinical value in predicting the OS for patients with HCC, and will provide a good reference between cancer research and SARS-CoV-2 and help individualized treatment in HCC.

中文翻译：

---

结合人类mRNAs的SARS-CoV-2蛋白的鉴定作为预测肝细胞癌总体生存的新特征。

严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）是导致2019年冠状病毒疾病的病毒（COVID-19）的影响已在癌症中通过结合特异性mRNA侵袭人类细胞而得到证实。因此，本文所述研究的目的是开发和验证结合人mRNA（SPBR）的新型SARS-CoV-2蛋白。）签名以预测肝细胞癌（HCC）的总体生存率（OS）。使用多变量Cox回归分析，确定了一组SPBR，以在Cancer Genome Atlas存储库队列中建立多基因签名。此外，基于特征和临床风险因素建立了诺模图，以改善单个患者的风险分层。外部验证是在国际癌症基因组协会（ICGC）队列中进行的。建立了六个SPBR签名，使用两个队列中具有不同OS的风险评分将患者分为两个风险组（所有p <0.0001）。多元回归分析表明该特征是肝癌的独立预测因子。此外，该签名在区分HCC和正常组织方面表现出出色的诊断能力。基因集富集分析表明，高危人群在细胞周期，DNA复制，癌症中的microRNA以及细胞因子与细胞因子受体的相互作用方面非常丰富。这种新颖的签名在预测肝癌患者的OS方面具有重要的临床价值，将为癌症研究与SARS-CoV-2之间的交流提供有益的参考，并有助于肝癌的个体化治疗。